about
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsAcute Stroke Imaging Research Roadmap II.Meta-analysis of randomized intra-arterial thrombolytic trials for the treatment of acute stroke due to middle cerebral artery occlusionClinical outcomes strongly associated with the degree of reperfusion achieved in target mismatch patients: pooled data from the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution studies.Ultra-acute CT perfusion imaging: A stroke in the scanner.Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.Power of an Adaptive Trial Design for Endovascular Stroke Studies: Simulations Using IMS (Interventional Management of Stroke) III Data.Comparison of magnetic resonance imaging mismatch criteria to select patients for endovascular stroke therapyA score based on age and DWI volume predicts poor outcome following endovascular treatment for acute ischemic strokeImproving dynamic susceptibility contrast MRI measurement of quantitative cerebral blood flow using corrections for partial volume and nonlinear contrast relaxivity: A xenon computed tomographic comparative studyRefining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data setCorrelation of AOL recanalization, TIMI reperfusion and TICI reperfusion with infarct growth and clinical outcomeTreatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale.Profiles of neurological outcome prediction among intensivists.Postthrombolysis hemorrhage risk is affected by stroke assessment bias between hemispheresDiagnostic Yield of Extended Cardiac Patch Monitoring in Patients with Stroke or TIA.Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.Early diffusion-weighted imaging reversal after endovascular reperfusion is typically transient in patients imaged 3 to 6 hours after onset.Effect of collateral blood flow on patients undergoing endovascular therapy for acute ischemic strokeGreater effect of stroke thrombolysis in the presence of arterial obstruction.Interhospital variation in reperfusion rates following endovascular treatment for acute ischemic stroke.Angiographic outcome of endovascular stroke therapy correlated with MR findings, infarct growth, and clinical outcome in the DEFUSE 2 trial.Reperfusion of very low cerebral blood volume lesion predicts parenchymal hematoma after endovascular therapy.Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.The growth rate of early DWI lesions is highly variable and associated with penumbral salvage and clinical outcomes following endovascular reperfusionA benchmarking tool to evaluate computer tomography perfusion infarct core predictions against a DWI standard.The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent.Response to endovascular reperfusion is not time-dependent in patients with salvageable tissueEffects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 TrialsCost comparison between the atraumatic and cutting lumbar puncture needles.Early diffusion-weighted imaging and perfusion-weighted imaging lesion volumes forecast final infarct size in DEFUSE 2Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study.Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke.Comparison of the response to endovascular reperfusion in relation to site of arterial occlusion.Perfusion MRI (Tmax and MTT) correlation with xenon CT cerebral blood flow in stroke patients.Yield of combined perfusion and diffusion MR imaging in hemispheric TIA.Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.Patients with single distal MCA perfusion lesions have a high rate of good outcome with or without reperfusionRisk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke.Clinical assessment of standard and generalized autocalibrating partially parallel acquisition diffusion imaging: effects of reduction factor and spatial resolution
P50
Q26823902-99CDE59A-7F24-4075-9087-F4823A5DB453Q30411115-124388F6-F8C4-450E-98C7-1A132A237085Q30425527-58A929FD-AC55-477A-992D-81715EE829B9Q30632319-7D71BD94-C0A9-4761-ACF5-FE25AEA44E9FQ30679938-88D964C8-0D22-4474-91E3-31595CCAB181Q31107456-BE352164-0574-445E-A68A-DE4A8D272227Q31145197-7C92F67C-636C-4948-82B6-957848AFC50AQ33555041-4E9A8518-07AC-4734-8953-654C2F5D1AEEQ33721817-916AB694-FA69-4134-B69F-FFEB0075CF90Q33778599-D9227FA3-6D4C-484D-94E8-F585680C97EBQ33865613-A074E27A-9965-4424-91AF-08D8DBE01FA6Q33875704-53FDB6F3-0176-4F54-BA75-2B3AA7A913A0Q33897269-C992BEE8-4F01-4FE6-BE1B-4AAA9C97E7C8Q34084806-28BC7DF2-498E-49EC-81A9-856F83B51431Q34647119-24817DDB-9C5B-4925-A172-FC503D6E2163Q34911990-0A4275E2-87FF-4A5E-9E85-34C81719263EQ35187798-78CCFA33-792C-4C6D-906F-01D161A088FBQ35414080-D2D40BE0-2334-4637-A66A-5EFE3C2064ECQ35414118-04754A83-C1BA-4D7F-9A97-3DB48A289DD2Q35492120-F41E119F-9154-404E-9619-B889C3816D4FQ35545304-A79D8629-E055-4F08-8968-95ACB72A52BCQ35545323-E5150EF2-4ECA-4940-BB51-5DCBB108D77FQ35554576-E68BB39E-A13B-4C11-94BE-58A8060A659BQ35752603-0965D13C-AC0C-4E49-A48F-AA1C5D7D2AF7Q35772296-6CE36AE4-F7E6-4EA2-84AC-A48622D9374CQ35867654-AD35CAD6-9675-4E3A-ACA0-4CAE743B92F9Q35880846-6BF0CEC1-B81E-4D84-AF80-8EA7AFD779C4Q36005674-279FEEFC-A080-433E-AB72-5A11A43D0848Q36099907-A36B9652-B9CD-498F-BB07-243B80EB4F9EQ36304551-CA2DE46B-5E0A-4FC6-9867-FF19758A8439Q36763688-29A0B08D-782F-43B4-B19C-8D14554449B8Q37133844-F829DC47-2B66-4391-A056-CE519B70DB9CQ37158942-36135D7A-17CB-42AD-8748-37DF961AF5F0Q37178785-0E8A63DD-EF86-4639-9069-A1770E1F5876Q37186742-0E77FF66-32D1-497A-A01F-9E099B08EFC5Q37186747-5413492E-6D2B-46A8-A147-AF7DACB2424BQ37301824-AD5893C7-6256-4B5A-82B2-FECFEC7974E8Q37535913-02AC9AA5-9C91-4F3A-A75E-5D482D65F758Q37701498-E5B281C5-7C08-492E-9A1C-FE0208B21E43Q37701552-A13C05AF-6279-49B1-B472-5F52D8443DFF
P50
description
researcher
@en
wetenschapper
@nl
name
Maarten G Lansberg
@ast
Maarten G Lansberg
@nl
Maarten G. Lansberg
@en
Maarten G. Lansberg
@es
type
label
Maarten G Lansberg
@ast
Maarten G Lansberg
@nl
Maarten G. Lansberg
@en
Maarten G. Lansberg
@es
prefLabel
Maarten G Lansberg
@ast
Maarten G Lansberg
@nl
Maarten G. Lansberg
@en
Maarten G. Lansberg
@es
P101
P1153
6602413209
P31
P496
0000-0002-3545-6927